AU7760898A - Antifungal composition containing beta-(1,6)-glucanase, and hosts incorporating same - Google Patents

Antifungal composition containing beta-(1,6)-glucanase, and hosts incorporating same Download PDF

Info

Publication number
AU7760898A
AU7760898A AU77608/98A AU7760898A AU7760898A AU 7760898 A AU7760898 A AU 7760898A AU 77608/98 A AU77608/98 A AU 77608/98A AU 7760898 A AU7760898 A AU 7760898A AU 7760898 A AU7760898 A AU 7760898A
Authority
AU
Australia
Prior art keywords
spp
glucanase
protein
plants
osmotin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU77608/98A
Other versions
AU743529B2 (en
Inventor
Jerome Hubertus Henricus Victor Custers
Wessel Lageweg
Maarten Hendrik Stuiver
Johanna Pieternella Els Van Deventer-Troost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Mogen BV
Original Assignee
Mogen International NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogen International NV filed Critical Mogen International NV
Publication of AU7760898A publication Critical patent/AU7760898A/en
Assigned to SYNGENTA MOGEN BV reassignment SYNGENTA MOGEN BV Amend patent request/document other than specification (104) Assignors: MOGEN INTERNATIONAL N.V.
Application granted granted Critical
Publication of AU743529B2 publication Critical patent/AU743529B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01075Glucan endo-1,6-beta-glucosidase (3.2.1.75)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8282Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for fungal resistance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Description

WO 98/49331 PCT/EP98/02580 ANTIFUNGAL COMPOSITION CONTAINING BETA-(1,6)-GLUCANASE, AND HOSTS INCORPORATING SAME FIELD OF THE INVENTION The present invention relates to a novel glucanase protein, a 5 combination of antifungal proteins and plants transformed with the glucanase or the combination, as well as methods of combatting fungal pathogens by causing said fungal pathogens to be contacted with said protein or proteins. The invention further relates to transformed plants which show 10 reduced susceptibility to fungal pathogens. BACKGROUND ART A protein with antifungal activity, isolated from TMV-induced tobacco leaves, which is capable of causing lysis of germinating 15 spores and hyphal tips of Phytophthora infestans and which causes the hyphae to grow at a reduced rate, was disclosed in W091/18984 Al and in Woloshuk et al. (Plant cell 3, 619-628, 1991). This protein, an osmotin, has an apparent molecular weight of about 24 kDa and was named AP24. Comparison of its complete amino acid 20 sequence, as deduced from the nucleic acid sequence of the AP24 gene, with proteins known from databases revealed that the protein was an osmotin-like protein. It has further been known that combination of antifungal agents such as chitinase and 9-(l,3)-glucanase (EP-A 0 440 304) 25 have a synergistic effect on the ability to destroy fungal pathogens. Recently (Lorito et al., Mol. Plant-Microb. Int. 9(3), 206 213, 1996) it has been shoum that also combinations of osmotin and other antifungal agents are effective. 30 WO 95/J1534 describes the 9-(l,6)-glucanase (or pustulanase) from Trichoderma harzianum as an agent which catalyzes the cleavage of 9-(1,6)-linkages in 9-glucan, a major component of the cell walls of fungal cells. It has also been found to act cooperativally with cellulases and chitinases against fungal plant pathogens such 35 as Botrytis, Phytophthora and Gibberella fujikori (de la Cruz, J. Bacteriol. 177(7), 1864-1871, 1995). Despite initial success in combating fungal pathogens, and the genetic engineering of plants capable of producing these 1 WO 98/49331 PCT/EP98/02580 antifungal proteins with activity against fungal pathogens there remains a need to identify and isolate other proteins and/or synergistic combinations with antifungal activity. 5 SUMMARY OF THE INVENTION The present invention provides for a new protein with 9 (1,6)-glucanase activity isolated from an edible fungus. More specifically the invention describes methods to isolate such a protein. 10 The present invention further provides an antifungal composition comprising a E-(l,6)-glucanase and optionally an osmotin. The present invention further provides a method for making plants pathogen resistant by transforming them with recombinant DNA 15 comprising a sequence coding for an osmotin and a sequence coding for a 9-(l,6)-glucanase. More specifically the osmotin is AP24, preferably having the amino acid sequence of SEQ ID NO:2, and preferably encoded by the nucleotide sequence of SEQ ID NO:1. 20 More specifically the 9-(l,6)-glucanase is of fungal origin, for instance from Trichoderma harzianum, or from edible fungi such as mushroom or shii-take. The invention also provides a recombinant DNA sequence according to the invention further comprising a transcriptional 25 initiation region and, optionally, a transcriptional termination region, so linked to said open reading frames as to enable the DNA to be transcribed in a living host cell when present therein, thereby producing RNAs which comprise said open reading frames. A preferred chimeric DNA sequence according to the invention is one, 30 wherein the RNAs comprising said open reading frames are capable of being translated into protein in said host cell, when present therein, thereby producing said proteins. The invention also embraces a chimeric DNA sequence comprising a DNA sequence according to the invention, which may be 35 selected from replicons, such as bacterial cloning plasmids and vectors, such as a bacterial expression vector, a (non-integrative) plant viral vector, a Ti-plasmid vector of Agrobacterium, such as a binary vector, and the like, as well as a host cell comprising a 2 WO 98/49331 PCT/EP98/02580 replicon or vector according to the invention, and which is capable of maintaining said replicon once present therein. Preferred according to that embodiment is a host cell which is a plant cell, said vector being a non-integrative viral vector. 5 The invention further provides a host cell stably incorporating in its genome a chimeric DNA sequence according to the invention, such as a plant cell, as well as multicellular hosts comprising such cells, or essentially consisting of such cells, such as plants. Especially preferred are plants characterised in 10 that the chimeric DNA according to the invention is expressed in at least a number of the plant's cells causing the said antifungal proteins to be produced therein. According to yet another embodiment of the invention a method for producing a protein with 9-(1,6)-glucanase activity is 15 provided, characterised in that a host cell according to the invention is grown under conditions allowing the said protein to be produced by said host cell, optionally followed by the step of recovering the protein from the host cells. Another part of the invention is directed to the targeting of 20 the osmotin and/or the 9-(l,6)-glucanase to the extracellular space. The invention also provides a method for obtaining plants with reduced susceptibility to fungi, comprising the steps of (a) introducing into ancestor cells which are susceptible of 25 regeneration into a whole plant, - a chimeric DNA sequence comprising open reading frames capable of encoding an osmotin and a 9-(l,6)-glucanase, said open reading frames being operatively linked to one or more transcriptional and translational regions and, optionally, a 30 transcriptional termination region, allowing the said proteins to be produced in a plant cell that is susceptible to infection by said fungus, and - a chimeric DNA sequence capable of encoding a plant selectable marker allowing selection of transformed ancestor cells 35 when said selectable marker is present therein, and (b) regenerating said ancestor cells into plants under conditions favouring ancestor cells which have the said selectable marker, and 3 WO 98/49331 PCT/EP98/02580 (c) identifying a plant which produces the proteins, thereby reducing the susceptibility of said plant to infection. Preferred according to the invention is a method characterised in that step (a) is performed using an Agrobacterium 5 tumefaciens strain capable of T-DNA transfer to plant cells and which harbours the said chimeric DNA cloned into binary vector pMOG800; another preferred method is when step (b) is performed in the presence of an antibiotic favouring cells which have a neomycin phosphotransferase or a cyanamid hydratase gene. 10 Legends to the figures. Figure 1. Purification of 91-6 glucanase by cation exchange chromatography. Three peaks of 91-6 glucanase activity can be seen, indicated by the numbers 1, 2, and 3 respectively. The chromatogram 15 of one representative run is shown. Other runs showed simmilar, if not identical, protein patterns and distribution of 91-6 glucanase activity. Protein is measured at A280. 91-6 glucanase activity is measured as described and is depicted as the absorbance at 510 nanometre. 20 Figure 2. Purification of 91-6 glucanase (pool no. 1, pooled fractions 4 and 5 from the cation exchange chromatography experiment; figure 1) by gel filtration chromatography. 81-6 glucanase activity elutes from the column at fractions 24-26. 25 Protein is measured at A280 and is depicted in milli-absorption units. 81-6 glucanase activity is measured as described and is depicted as the absorbance at 510 nanometre. Figure 3. SDS-PAGE analysis of the protein fractions of pool no. 1 30 after gel filtration chromatography (figure 2). Figure 4. Purification of 91-6 glucanase (pool no. 1, pooled fractions 25 and 26 from the gel filtration chromatography experiment; figure 2) by chromatophocusing chromatography on a Mono 35 P exchanger column. 81-6 glucanase activity elutes from the column at fractions 11-12, corresponding to a pH of about 6.7. Protein is measured at A280 and is depicted in milli-absorption units. 4 WO 98/49331 PCT/EP98/02580 Figure 5. SDS-PAGE analysis of the f1-6 glucanase activity containing fractions of pool no. 1 after chromatophocusing chromatography (figure 4). 5 Figure 6. Purification of 91-6 glucanase (pool no. 2, pooled fractions 10, 11, and 12 from the cation exchange chromatography experiment; figure 1) by gel filtration chromatography. 91-6 glucanase activity elutes from the column at fractions 15-17. Protein is measured at A280 and is depicted in milli-absorption 10 units. 91-6 glucanase activity is measured as described and is depicted as the absorbance at 510 nanometre. Figure 7. SDS-PAGE analysis of the protein fractions of pool no. 2 after gel filtration chromatography (figure 6). The arrow points 15 towards the presumed 8,1-6 glucanase bands. Figure 8. Purification of i1-6 glucanase (pool no. 2, fraction 16 from the gel filtration chromatography experiment; figure 6) by chromatofocusing chromatography on a Mono P exchanger column. S1-6 20 glucanase activity elutes from the column at fractions 3-5, corresponding to the flow-through of the column, meaning that the isoelectric point is above pH 6.8. Protein is measured at A280 and is depicted in milli-absorption units. 25 Figure 9. SDS-PAGE analysis of the 8,1-6 glucanase activity containing fractions of pool no. 2 after chromatophocusing chromatography (figure 8). The arrow points towards the 8,1-6 glucanase band. 30 Figure 10. Purification of 8,1-6 glucanase (pool no. 3, pooled fractions 15, 16, and 17 from the cation exchange chromatography experiment; figure 1) by gel filtration chromatography. 91-6 glucanase activity elutes from the column at fractions 15-18. Protein is measured at A280 and is depicted in milli-absorption 35 units. 8,1-6 glucanase activity is measured as described and is depicted as the absorbance at 510 nanometre. 5 WO 98/49331 PCT/EP98/02580 Figure 11. Double reciprocal plot showing 91-6 glucanase activity as a function of pustulan concentration. Fraction number 4 from the chromatophocusing column from pool no. 2 (figure 8) was used as source of ,1-6 glucanase activity. ,1-6 glucanase activity is 5 measured as described and is depicted as the absorbance at 510 nanometre. Figure 12. Effect of AP24 and ,1-6 glucanase on in vitro growth of Fusarium oxysporum . The fungus was grown in a microtiter plate 10 assay as described, in the presence of 5pg/ml AP24 plus 5g/ml 91-6 glucanase (91-6/AP24) or in the absence of these proteins (Ref). Fungal growth was followed in time by reading the absorbance at 620 nanometres in a microtiter plate reader. 15 Figure 13. Effect of AP24 and ,1-6 glucanase on in vitro growth of Paecilomyces variottii. Same assay as depicted in fig. 12. Figure 14. Effect of AP24 and ,1-6 glucanase on in vitro growth of Penicillium roqueforti. Same assay as depicted in fig. 12. 20 DETAILED DESCRIPTION OF THE INVENTION The 9-(l,6)-glucanase protein according to the present invention may be obtained by isolating it from any suitable edible fungus source material containing it. Edible fungi in this respect 25 means fungi which are commonly eaten. A particularly suitable source comprises fruit bodies and or mycelium of mushrooms (Agaricus spp.), oyster mushrooms (Pleurotus ostreatus), shii-take (Lentinus edodes) or of other commonly eaten fungi such as Volvariella spp., Tricholoma matsutake, Tuber uncinatum, Tuber 30 melanosporum, Tuber spp., Stephensia spp., Cantharellus spp., Pleurotus spp., Coprinus spp., Lepiota spp., Marasmius spp., Polysporus spp., Verpa spp., Tricholoma spp., Terfezia spp., Morchella spp., Cyttaria spp and fungi routinely used in the production of cheese such as Penicillium roqueforti and P. 35 camemberti. 6 WO 98/49331 PCT/EP98/02580 Alternatively, proteins according to the invention may be obtained by cloning DNA comprising an open reading frame capable of encoding said protein, or the precursor thereof, linking said open reading frame to a transcriptional, and optionally a translational 5 initiation and transcriptional termination region, inserting said DNA into a suitable host cell and allowing said host cell to produce said protein. Subsequently, the protein may be recovered from said host cells, preferably after secretion of the protein into the culture medium by said host cells. Alternatively, said 10 host cells may be used directly in a process of combating fungal pathogens according to the invention as a pesticidal acceptable composition. Host cells suitable for use in a process of obtaining a protein according to the invention may be selected from prokaryotic 15 microbial hosts, such as bacteria e.g. Agrobacterium, Bacillus, Cyanobacteria, E.coli , Pseudomonas, and the like, as well as eukaryotic hosts including yeasts, e.g. Saccharomyces cerevisiae, fungi, e.g. Trichoderma and plant cells, including protoplasts. The word protein means a sequence of amino acids connected 20 trough peptide bonds. Polypeptides or peptides are also considered to be proteins. Muteins of the protein of the invention are proteins that are obtained from the proteins depicted in the sequence listing by replacing, adding and/or deleting one or more amino acids, while still retaining their glucanase activity. Such 25 muteins can readily be made by protein engineering in vivo, e.g. by changing the open reading frame capable of encoding the protein such that the amino acid sequence is thereby affected. As long as the changes in the amino acid sequences do not altogether abolish the glucanase activity such muteins are embraced in the present 30 invention. The present invention provides a chimeric DNA sequence which comprises an open reading frame capable of encoding the protein according to the invention or a combination of osmotin and 9-(l,6) glucanase. The expression chimeric DNA sequence shall mean to 35 comprise any DNA sequence which comprises DNA sequences not naturally found in nature. For instance, chimeric DNA shall mean to comprise DNA comprising the said open reading frame in a non natural location of the host genome, notwithstanding the fact that 7 WO 98/49331 PCT/EP98/02580 said host genome normally contains a copy of the said open reading frame in its natural chromosomal location. Similarly, the said open reading frame may be incorporated in the host genome wherein it is not naturally found, or in a replicon or vector where it is not 5 naturally found, such as a bacterial plasmid or a viral vector. Chimeric DNA shall not be limited to DNA molecules which are replicable in a host, but shall also mean to comprise DNA capable of being ligated into a replicon, for instance by virtue of specific adaptor sequences, physically linked to the open reading 10 frame according to the invention. The open reading frame may or may not be linked to its natural upstream and downstream regulatory elements. The open reading frame may be derived from a genomic library. In this latter it may contain one or more introns separating the 15 exons making up the open reading frame that encodes a protein according to the invention. The open reading frame may also be encoded by one uninterrupted exon, or by a cDNA to the mRNA encoding a protein according to the invention. Open reading frames according to the invention also comprise those in which one or more 20 introns have been artificially removed or added. Each of these variants is embraced by the present invention. The open reading frame coding for the osmotin preferably comprises a nucleotide sequence that codes for a protein as is depicted in SEQ ID NO:2. Most preferably the nucleotide sequence 25 comprises the nucleotide sequence of the open reading frame depicted in SEQ ID NO:1. The open reading frame coding for the 9-(l,6)-glucanase can either be composed of the sequence coding for the protein which can be derived from Trichoderma harzianum, or it can be derived from an 30 edible fungus or a plant. In order to be capable of being expressed in a host cell a chimeric DNA according to the invention will usually be provided with regulatory elements enabling it to be recognised by the biochemical machinery of the host and allowing for the open reading 35 frame to be transcribed and/or translated in the host. It will usually comprise a transcriptional initiation region which may be suitably derived from any gene capable of being expressed in the host cell of choice, as well as a translational initiation region 8 WO 98/49331 PCT/EP98/02580 for ribosome recognition and attachment. In eukaryotic cells, an expression cassette usually comprises in addition a transcriptional termination region located downstream of said open reading frame, allowing transcription to terminate and polyadenylation of the 5 primary transcript to occur. In addition, the codon usage may be adapted to accepted codon usage of the host of choice. The principles governing the expression of a chimeric DNA construct in a chosen host cell are commonly understood by those of ordinary skill in the art and the construction of expressible chimeric DNA 10 constructs is now routine for any sort of host cell, be it prokaryotic or eukaryotic. In order for the open reading frame to be maintained in a host cell it will usually be provided in the form of a replicon comprising said open reading frame according to the invention 15 linked to DNA which is recognised and replicated by the chosen host cell. Accordingly the selection of the replicon is determined largely by the host cell of choice. Such principles as govern the selection of suitable replicons for a particular chosen host are well within the realm of the ordinary skilled person in the art. 20 A special type of replicon is one capable of transferring itself, or a part thereof, to another host cell, such as a plant cell, thereby co-transferring the open reading frame according to the invention to said plant cell. Replicons with such capability are herein referred to as vectors. An example of such vector is a 25 Ti-plasmid vector which, when present in a suitable host, such as Agrobacterium tumefaciens, is capable of transferring part of itself, the so-called T-region, to a plant cell. Different types of Ti-plasmid vectors (vide: EP 0 116 718 Bl) are now routinely being used to transfer chimeric DNA sequences into plant cells, or 30 protoplasts, from which new plants may be generated which stably incorporate said chimeric DNA in their genomes. A particularly preferred form of Ti-plasmid vectors are the so-called binary vectors as claimed in (EP 0 120 516 B1 and US 4,940,838). Other suitable vectors, which may be used to introduce DNA according to 35 the invention into a plant host, may be selected from the viral vectors, e.g. non-integrative plant viral vectors, such as derivable from the double stranded plant viruses (e.g. CaMV) and single stranded viruses, gemini viruses and the like. The use of 9 WO 98/49331 PCT/EP98/02580 such vectors may be advantageous, particularly when it is difficult to stably transform the plant host. Such may be the case with woody species, especially trees and vines. The expression "host cells incorporating a chimeric DNA 5 sequence according to the invention in their genome" shall mean to comprise cells, as well as multicellular organisms comprising such cells, or essentially consisting of such cells, which stably incorporate said chimeric DNA into their genome thereby maintaining the chimeric DNA, and preferably transmitting a copy of such 10 chimeric DNA to progeny cells, be it through mitosis or meiosis. According to a preferred embodiment of the invention plants are provided, which essentially consist of cells which incorporate one or more copies of said chimeric DNA into their genome, and which are capable of transmitting a copy or copies to their progeny, 15 preferably in a Mendelian fashion. By virtue of the transcription and translation of the chimeric DNA according to the invention in some or all of the plant's cells, those cells as produce the antifungal proteins will show enhanced resistance to fungal infections. Although the principles as govern transcription of DNA 20 in plant cells are not always understood, the creation of chimeric DNA capable of being expressed in substantially a constitutive fashion, that is, in substantially most cell types of the plant and substantially without serious temporal and/or developmental restrictions, is now routine. Transcription initiation regions 25 routinely in use for that purpose are promoters obtainable from the cauliflower mosaic virus, notably the 35S RNA and 19S RNA transcript promoters and the so-called T-DNA promoters of Agrobacterium tumefaciens, in particular to be mentioned are the nopaline synthase promoter, octopine synthase promoter (as 30 disclosed in EP 0 122 791 Bl) and the mannopine synthase promoter. In addition plant promoters may be used, which may be substantially constitutive, such as the rice actin gene promoter, or e.g. organ specific, such as the root-specific promoter. Alternatively, pathogen-inducible promoters may be used such as the PRP1 promoter 35 (also named gstl promoter) obtainable from potato (Martini N. et al. (1993), Mol. Gen. Genet. 263, 179-186). The choice of the promoter is not essential, although it must be said that constitutive high-level promoters are slightly preferred. It is 10 WO 98/49331 PCT/EP98/02580 further known that duplication of certain elements, so-called enhancers, may considerably enhance the expression level of the DNA under its regime (vide for instance: Kay R. et al. (1987), Science 236, 1299-1302: the duplication of the sequence between -343 and 5 90 of the CaMV 35S promoter increases the activity of that promoter). In addition to the 35S promoter, singly or doubly enhanced, examples of high-level promoters are the light-inducible ribulose bisphosphate carboxylase small subunit (rbcSSU) promoter and the chlorophyll a/b binding protein (Cab) promoter. Also 10 envisaged by the present invention are hybrid promoters, which comprise elements of different promoter regions physically linked. A well known example thereof is the so-called CaMV enhanced mannopine synthase promoter (US Patent 5,106,739), which comprises elements of the mannopine synthase promoter linked to the CaMV 15 enhancer. As regards the necessity of a transcriptional terminator region, it is generally believed that such a region enhances the reliability as well as the efficiency of transcription in plant cells. Use thereof is therefore strongly preferred in the context 20 of the present invention. Another aspect of gene expression in transgenic plants concerns the targeting of antifungal proteins to the extracellular space (apoplast). Naturally intracellularly occurring proteins, among which proteins according to the present invention, may be 25 caused to be targeted to the apoplast by removal of the C-terminal propeptide, e.g. by modifying the open reading frame at its 3' end such that protein is caused to be C-terminally truncated. A certain number of amino acids of the C-terminal part of the protein was found to be responsible for targeting of the protein to the vacuole 30 (e.g. vide WO91/18984 Al). By introducing a translational stopcodon in the open reading frame the truncated protein is caused to be targeted to the apoplast. The invention can be practiced in all plants, even in plant 35 species that are presently not amenable for transformation, as the amenability of such species is just a matter of time and because transformation as such is of no relevance for the principles underlying the invention. Hence, plants for the purpose of this 11 WO 98/49331 PCT/EP98/02580 description shall include angiosperms as well as gymnosperms, monocotyledonous as well as dicotyledonous plants, be they for feed, food or industrial processing purposes; included are plants used for any agricultural or horticultural purpose including 5 forestry and flower culture, as well as home gardening or indoor gardening, or other decorative purposes. Transformation of plant species is now routine for an impressive number of plant species, including both the Dicotyledoneae as well as the Monocotyledoneae. In principle any 10 transformation method may be used to introduce chimeric DNA according to the invention into a suitable ancestor cell. Methods may suitably be selected from the calcium/polyethylene glycol method for protoplasts (Krens, F.A. et al., 1982, Nature 296, 72 74; Negrutiu I. et al, June 1987, Plant Mol. Biol. 8, 363-373), 15 electroporation of protoplasts (Shillito R.D. et al., 1985 Bio/Technol. 3, 1099-1102), microinjection into plant material (Crossway A. et al., 1986, Mol. Gen. Genet. 202, 179-185), (DNA or RNA-coated) particle bombardment of various plant material (Klein T.M. et al., 1987, Nature 327, 70), infection with (non 20 integrative) viruses, in planta Agrobacterium tumefaciens mediated gene transfer by infiltration of adult plants or transformation of mature pollen or microspores (EP 0 301 316) and the like. A preferred method according to the invention comprises Agrobacterium-mediated DNA transfer. Especially preferred is the 25 use of the so-called binary vector technology as disclosed in EP A 120 516 and U.S. Patent 4,940,838). Although considered somewhat more recalcitrant towards genetic transformation, monocotyledonous plants are amenable to transformation and fertile transgenic plants can be regenerated 30 from transformed cells or embryos, or other plant material. Presently, preferred methods for transformation of monocots are microprojectile bombardment of embryos, explants or suspension cells, and direct DNA uptake or (tissue) electroporation (Shimamoto, et al, 1989, Nature 338, 274-276). Transgenic maize 35 plants have been obtained by introducing the Streptomyces hygroscopicus bar-gene, which encodes phosphinothricin acetyltransferase (an enzyme which inactivates the herbicide phosphinothricin), into embryogenic cells of a maize suspension 12 WO 98/49331 PCT/EP98/02580 culture by microprojectile bombardment (Gordon-Kamm, 1990, Plant Cell, 2, 603-618). The introduction of genetic material into aleurone protoplasts of other monocot crops such as wheat and barley has been reported (Lee, 1989, Plant Mol. Biol. 13, 21-30). 5 Wheat plants have been regenerated from embryogenic suspension culture by selecting embryogenic callus for the establishment of the embryogenic suspension cultures (Vasil, 1990 Bio/Technol. 8, 429-434). The combination with transformation systems for these crops enables the application of the present invention to monocots. 10 Monocotyledonous plants, including commercially important crops such as rice and corn are also amenable to DNA transfer by Agrobacterium strains (vide WO 94/00977; EP 0 159 418 Bl; Gould J, Michael D, Hasegawa O, Ulian EC, Peterson G, Smith RH, (1991) Plant. Physiol. 95, 426-434). 15 To obtain transgenic plants capable of constitutively expressing more than one chimeric gene, a number of alternatives are available including the following: A. The use of DNA, e.g a T-DNA on a binary plasmid, with a number of modified genes physically coupled to a second selectable marker 20 gene. The advantage of this method is that the chimeric genes are physically coupled and therefore migrate as a single Mendelian locus. B. Cross-pollination of transgenic plants each already capable of expressing one or more chimeric genes, preferably coupled to a 25 selectable marker gene, with pollen from a transgenic plant which contains one or more chimeric genes coupled to another selectable marker. Afterwards the seed, which is obtained by this crossing, maybe selected on the basis of the presence of the two selectable markers, or on the basis of the presence of the chimeric genes 30 themselves. The plants obtained from the selected seeds can afterwards be used for further crossing. In principle the chimeric genes are not on a single locus and the genes may therefore segregate as independent loci. C. The use of a number of a plurality chimeric DNA molecules, e.g. 35 plasmids, each having one or more chimeric genes and a selectable marker. If the frequency of co-transformation is high, then selection on the basis of only one marker is sufficient. In other 13 WO 98/49331 PCT/EP98/02580 cases, the selection on the basis of more than one marker is preferred. D. Consecutive transformation of transgenic plants already containing a first, second, (etc), chimeric gene with new chimeric 5 DNA, optionally comprising a selectable marker gene. As in method B,the chimeric genes are in principle not on a single locus and the chimeric genes may therefore segregate as independent loci. E. Combinations of the above mentioned strategies. The actual strategy may depend on several considerations as 10 maybe easily determined such as the purpose of the parental lines (direct growing, use in a breeding programme, use to produce hybrids) but is not critical with respect to the described invention. It is known that practically all plants can be regenerated 15 from cultured cells or tissues. The means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts or a petri plate containing transformed explants is first provided. Shoots may be induced directly, or indirectly from callus via organogenesis or embryogenesis and 20 subsequently rooted. Next to the selectable marker, the culture media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Efficient regeneration will depend on the medium, on 25 the genotype and on the history of the culture. If these three variables are controlled regeneration is usually reproducable and repeatable. After stable incorporation of the transformed gene sequences into the transgenic plants, the traits conferred by them can be 30 transferred to other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed. To select or screen for transformed cells, it is preferred to 35 include a marker gene linked to the plant expressible gene according to the invention to be transferred to a plant cell. The choice of a suitable marker gene in plant transformation is well within the scope of the average skilled worker; some examples of 14 WO 98/49331 PCT/EP98/02580 routinely used marker genes are the neomycin phosphotransferase genes conferring resistance to kanamycin (EP-B 131 623), the glutathion-S-transferase gene from rat liver conferring resistance to glutathione derived herbicides (EP-A 256 223), glutamine 5 synthetase conferring upon overexpression resistance to glutamine synthetase inhibitors such as phosphinothricin (WO 87/05327), the acetyl transferase gene from Streptomyces viridochromogenes conferring resistance to the selective agent phosphinothricin (EP-A 275 957), the gene encoding a 5-enolshikimate-3- phosphate synthase 10 (EPSPS) conferring tolerance to N-phosphonomethylglycine, the bar gene conferring resistance against Bialaphos (e.g. WO 91/02071), the cyanamid hydratase gene and the like. The actual choice of the marker is not crucial as long as it is functional (i.e. selective) in combination with the plant cells of choice. 15 The marker gene and the gene of interest do not have to be linked, since co-transformation of unlinked genes (U.S. Patent 4,399,216) is also an efficient process in plant transformation. Preferred plant material for transformation, especially for dicotyledonous crops are leaf-discs which can be readily 20 transformed and have good regenerative capability (Horsch R.B. et al., (1985) Science 227, 1229-1231). Another embodiment of the present invention is an antifungal composition comprising a 9-(l,6)-glucanase and an osmotin. It has been found that both components act synergistically to yield an 25 antifungal effect in vitro. Such antifungal effects are very useful in food applications. Especially low-fat spreads, cheese and other dairy products, tea-based beverages, fruit- and tomato-based products are vulnerable food products in this respect. Combinations of antifungal compounds which act synergistically are preferable to 30 combat fungi in food applications because less preservative substance is needed. Furthermore, it is possible to use components from a natural source, which allows reduction of non-natural food additives which is preferable both from a nutritional and from a occupational health viewpoint. 35 It will be understood that from a regulatory viewpoint it would be preferable to use the 9-(,6)-glucanase which, as put forward in this invention, can be derived from edible fungi, such as mushrooms and shii-take. 15 WO 98/49331 PCT/EP98/02580 Beside the active ingredients the composition according to the invention may contain auxiliary ingredients which are usual for fungi combatting compositions and which may include solid diluents, solvents, stabilizers and pH-regulators. The composition may be in 5 the form of a powder, a paste or a liquid, depending on the envisaged way of application. The composition is particularly suitable as a preservative for combatting fungi in food, but it can be used as well for preventing or combatting undesired fungal growth on other products, such as 10 cosmetic products, where the fungal growth inhibiting composition is not only useful to keep the surface of the cosmetic product (e.g. soap) free of fungi, but also for an advantageous effect on the skin which is treated with such product, e.g. a shampoo being applied to a scalp with a fungal affliction. 15 Both the antifungal composition according to the invention as the plant transformed with the gene coding for the protein of the invention may contain additional antifungal components. Examples of proteins that may be used in combination with the 20 proteins according to the invention include, but are not limited to, 9-(1,3)-glucanases and chitinases which are obtainable from barley (Swegle M. et al., 1989, Plant Mol. Biol. 12, 403-412; Balance G.M. et al., 1976, Can. J. Plant Sci. 56, 459-466 ; Hoj P.B. et al., 1988, FEBS Lett. 230, 67-71; Hoj P.B. et al., 1989, 25 Plant Mol. Biol. 13, 31-42 1989), bean (Boller T. et al., 1983, Planta 157, 22-31; Broglie K.E. et al. 1986, Proc. Natl. Acad. Sci. USA 83, 6820-6824; V6geli U. et al., 1988 Planta 174, 364-372); Mauch F. & Staehelin L.A., 1989, Plant Cell 1, 447-457); cucumber (Motraux J.P. & Boller T. (1986), Physiol. Mol. Plant Pathol. 28, 30 161-169); leek (Spanu P. et al., 1989, Planta 177, 447-455); maize (Nasser W. et al., 1988, Plant Mol. Biol. 11, 529-538), oat (Fink W. et al., 1988, Plant Physiol. 88, 270-275), pea (Mauch F. et al. 1984, Plant Physiol. 76, 607-611; Mauch F. et al., 1988, Plant Physiol. 87, 325-333), poplar (Parsons, T.J. et al, 1989, Proc. 35 Natl. Acad. Sci. USA 86, 7895-7899), potato (Gaynor J.J. 1988, Nucl. Acids Res. 16, 5210; Kombrink E. et al. 1988, Proc. Natl. Acad. Sci. USA 85, 782-786; Laflamme D. and Roxby R., 1989, Plant Mol. Biol. 13, 249-250), tobacco (e.g. Legrand M. et al. 1987, 16 WO 98/49331 PCT/EP98/02580 Proc. Natl. Acad. Sci. USA 84, 6750-6754; Shinshi H. et al. 1987, Proc. Natl. Acad. Sci. USA 84, 89-93), tomato (Joosten M.H.A. & De Wit P.J.G.M. 1989, Plant Physiol. 89, 945-951), wheat (Molano J. et al., 1979, J. Biol. Chem. 254, 4901-4907), and the like. 5 In this context it should be emphasised that plants already containing chimeric DNA capable of encoding antifungal proteins may form a suitable genetic background for introducing chimeric DNA according to the invention, for instance in order to enhance resistance levels, or broaden the resistance. The cloning of other 10 genes corresponding to proteins that can suitably be used in combination with DNA, and the obtention of transgenic plants, capable of relatively over-expressing same, as well as the assessment of their effect on pathogen resistance in planta , is now within the scope of the ordinary skilled person in the art. 15 The obtention of transgenic plants capable of expressing, or relatively over-expressing, proteins according to the invention is a preferred method for counteracting the damages caused by pathogens such as fungi, as will be clear from the above description. 20 Plants, or parts thereof, which relatively over-express the protein combination according to the invention, including plant varieties, with improved resistance against diseases, especially diseases caused by fungi may be grown in the field, in the greenhouse, or at home or elsewhere. Plants or edible parts thereof 25 may be used for animal feed or human consumption, or may be processed for food, feed or other purposes in any form of agriculture or industry. Agriculture shall mean to include horticulture, arboriculture, flower culture, and the like. Industries which may benefit from plant material according to the 30 invention include but are not limited to the pharmaceutical industry, the paper and pulp manufacturing industry, sugar manufacturing industry, feed and food industry, enzyme manufacturers and the like. The advantages of the plants, or parts thereof, according to the 35 invention are the decreased need for fungicide treatment, thus lowering costs of material, labour, and environmental pollution, or prolonging shelf-life of products (e_. fruit, seed, and the like) of such plants. Plants for the purpose of this invention shall mean 17 WO 98/49331 PCT/EP98/02580 multicellular organisms capable of photosynthesis, and subject to some form of fungal disease. They shall at least include angiosperms as well as gymnosperms, monocotyledonous as well as dicotyledonous plants. 5 The phrase "plants which relatively over-express a protein" shall mean plants which contain cells expressing a transgene encoded protein which is either not naturally present in said plant, or if it is present by virtue of an endogenous gene encoding an identical protein, not in the same quantity, or not in the same 10 cells, compartments of cells, tissues or organs of the plant. It is known for instance that proteins which normally accumulate intracellularly may be targeted to the apoplastic space. The following state of the art may be taken into consideration, especially as illustrating the general level of skill in the art to 15 which this invention pertains. EP-A 392 225 A2; EP-A 440 304 Al; EP-A 460 753 A2; W090/07001 Al; US Patent 4,940,840. Evaluation of transgenic plants 20 Subsequently transformed plants are evaluated for the presence of the desired properties and/or the extent to which the desired properties are expressed. A first evaluation may include the level of expression of the newly introduced genes, the level of fungal resistance of the transformed plants, stable heritability of 25 the desired properties, field trials and the like. Secondly, if desirable, the transformed plants can be crossbred with other varieties, for instance varieties of higher commercial value or varieties in which other desired characteristics have already been introduced, or used for the 30 creation of hybrid seeds, or be subject to another round of transformation and the like. EXPERIMENTAL PART 35 Standard methods for the isolation, manipulation and amplification of DNA, as well as suitable vectors for replication of recombinant DNA, suitable bacterium strains, selection markers, media and the like are described for instance in Maniatis et al., molecular 18 WO 98/49331 PCT/EP98/02580 cloning: A Laboratory Manual 2nd. edition (1989) Cold Spring Harbor Laboratory Press; DNA Cloning: Volumes I and II (D.N. Glover ed. 1985); and in: From Genes To Clones (E.-L. Winnacker ed. 1987). 5 Enzyme assay S(1,6) glucanase activity was determined by measuring the amount of reducing sugars released from pustulan at 37 0 C. Pustulan was dissolved in hot buffer (50mM Kac, pH 5.0) and, after cooling, remained in solution without precipitation. The standard assay 10 (0.5ml) contained the enzyme preparation, 1.3 mg of pustulan and 50mM Kac, pH 5.0. 9(1,3) glucanase activity was assayed with laminarin as the reaction substrate (1.25 mg of laminarin in 0.5ml 50mM NaAc, pH 5.5). 15 The reducing sugars were determined according to Nelson, N., J. Biol. Chem. 153, 375-380, 1944. EXAMPLE 1 20 Purifiation of 9(1,6) glucanase from edible mushrooms via pustulan precipitation. It was investigated whether edible mushrooms contained E-(1,6) glucanase activity. We were able to demonstrate 9-(l,6)-glucanase 25 activity in mushrooms. As a positive control we used a Trichoderma extract that is sold commercially as Novozym 234. This extract is known to contain substantial amounts of 9(l,6)glucanase enzymatic activity. 30 Table 1 9-(l,6)-glucanase activities in different extracts Sample specific activity (nkat/mg) Agaricus bisporus 1.8 TMV infected 0 tobacco Sunflower 0 Novozym 234 17 19 WO 98/49331 PCT/EP98/02580 Mushrooms do contain 9-(,6)-glucanase activity, its specific activity being about one order of magnitude lower compared to the Trichoderma derived enzyme. In protein fractions of sunflower and 5 TMV- infected tobacco no activity could be detected. Five different mushrooms were tested for 9-(l,6)-glucanase activity and two mushrooms with the highest specific activity were used for purification of the enzyme. 10 Table 2 Mushroom extract Specific activity (nkat/mg protein) Agaricus bisporus 0.35 Cave mushrooms 0.9 Chestnut mushrooms 0.5 Oyster mushrooms 1.4 Shii Take 2.6 The newly determined specific activity for the Agaricus bisporus extract is substantial lower than that depicted in table 1. The 15 extract used for the data of Table 2 is a different extract, and we do not know the reason for this discrepancy. The extracts of Oyster mushrooms and Shii Take were used for further purification. Purification is as follows: An extract of fungi is made by chopping and grinding them in a buffer containing 0.5 M NaAc pH=5.2 + 0.1% 20 B-mercaptoethanol, then freezing in liquid nitrogen and mincing the fungi in a blender. Then the crude extract was filtered through 5 layers of cheese cloth. Particles were removed from this solution by centrifugation for 1 hour at 9500 rpm in a Sorvall S-30 rotor. The crude protein extract (homogenate) was then further purified by 25 ammonium sulfate precipitation, the -(i1,6)-glucanase activity was precipitated at 80% saturation. The pellet was dialysed into 50 mM NaAc (pH=5.2) buffer. For pustulan adsorption and digestion, this extract was mixed with finely dispersed pustulan particles, incubated for 20 minutes at room temperature, and the mixture 30 centrifuged for 10 minutes at maximum speed in a microfuge 20 WO 98/49331 PCT/EP98/02580 centrifuge. Then the pellets were washed twice in 70 mM Potassium phosphate buffer pH 6.0 containing 1 M NaCl. The enzyme was released by overnight incubation of the particles in a buffer containing 50 mM Kac (pH=5.5) in the presence of protease 5 inhibitors and azide to prevent microbial growth. Further purification of the extract was performed by chromatofocusing on a Mono-P column (Pharmacia), in a buffer containing 25 mM imidazole HC1 with a pH gradient of 7.4 to 4.0. Elution of the Oystermushroom enzyme occurred around pH 5.6. The Shii take enzyme eluted at pH 10 4.5 Data obtained with the mentioned purification scheme are depicted in table 3. Table 3 Oyster mushrooms Total activity (nkat) Specific activity (nkat/mg) Homogenate 233.5 1.43 AS fraction 134.9 2.22 Pustulan fraction 0.68 >50 Mono-P peak 5.4 >180 Shii Take Homogenate 60.1 2.6 AS fraction 21.1 0.85 Pustulan fraction 0.26 >30 Mono-P Deak 0.46 >230 15 The crude fungi homogenates contain, besides the 9-(l,6)-glucanase activity (see above), also 9-(l,3)-glucanase activity and chitinase activity. Specific activities for 9-(l,3)-glucanase are 9.1 and 30.2 nkat/mg for Oyster mushrooms and Shii Take respectively. The activities for chitinase are 13.8 and 53.5 OD(550nm) units/mg 20 respectively. The purified proteins (Mono-P fractions) contained no detectable activity for 9-(l,3)-glucanase, however, a small amount of chitinase activity was still present. Both Mono-P peak fractions were subjected to SDS-PAGE. No protein bands were detectable in the Shii Take 9-(l,6)-glucanase 25 peak fraction. The Oyster mushroom E-(l,6)glucanase peakfraction 21 WO 98/49331 PCTIEP98/02580 contained two closely spaced protein bands of approximately 50 51kDa after silver staining of the gel. 9-(1,6)-glucanase from Trichoderma is approximately 43kDa. 5 Example 2 Purification of E(l,6) glucanase from edible mushrooms Oyster mushrooms (Pleurotus ostreatus) were homogenized at 4 0 C in 50mM KAc pH 5.0, 0.1% E-mercaptoethanol (mushrooms : buffer 10 = 1.5 : 1 (w/v)), using a Waring blender. The homogenate was centrifuged for 30 minutes at 9,000 g at 4 0 C in a Sorvall SS34 rotor. Subsequently, solid ammonium sulphate was added gradually to a concentration of 2M. Aggregated proteins were removed by centrifugation for 30 minutes at 9,000 g at 4 0 C in a Sorvall SS34 15 rotor. Hydrophobic interaction chromatography The supernatant was filtered over a paper filter and applied to a phenyl-sepharose 6FastFlow High sub column (l.6xl5cm) pre 20 equilibrated with 2M ammonium sulphate in 50mM potassium-acetate buffer, pH 5.0 at a flow rate of 10 ml/min. The column was washed with at least 10 column volumes of buffer A after which bound protein was eluted with a negative linear gradient ending at 50mM potassium acetate buffer pH 5.0. This was followed by a positive 25 gradient starting with 50mM potassium acetate buffer and ended with the same acetate buffer containing 50% ethylene glycol (flow rate 5 ml/min.). Fractions of 10 ml were collected and assayed for S (1,6)-glucanase activity. Fractions containing 9-(1,6)-glucanase activity were pooled and concentrated in an Amicon ultra-filtration 30 device with a molecular weight cut-off point of 10 kDa. Cation exchange chromatography The concentrated protein solution was diluted 10 times with 25mM sodium acetate buffer pH 4.0 and subjected to cation exchange 35 chromatography on a small Resource S column (Pharmacia). Unbound protein was washed off with 2 column volumes of 25mM sodium acetate buffer pH 4.0. Retained proteins were eluted with a linear gradient ending at 250 mM NaCl in 25mM sodium acetate pH 4.0 after 40 column 22 WO 98/49331 PCT/EP98/02580 volumes. Fractions of 2 ml were collected and and assayed for 8 (1,6)-glucanase activity. Three protein peaks containing 9-(l,6) glucanase activity were found (see fig. 1). Fractions containing these protein peaks were pooled seperately, resulting in three 5 pools (pool no. 1; 2; 3) containing 9-(l,6)-glucanase activity. The pooled protein fractions were brought to pH 5.0 by adding 1/10 volume of lM potassium acetate pH 5.0. Each pool was concentrated in an Amicon ultra-filtration device with a molecular cut-off point of 10 kDa to about 0.5-1.0 ml. 10 Gelfiltration chromatography and subsequent chromatofocusing The pools were subjected to gelfiltration chromatography (Superdex 75, 10/30, Pharmacia), with 200mM NaCl in 50mM potassium 15 acetate, pH 5.0 as the running buffer. The sample volume was 200 pl; flow rate 0.5 ml/min, fractions of 0.5 ml were collected. Pool # 1. The antifungal activity elutes from the gel-filtration column 20 (fig. 2) at about 12kDa, based on standard marker proteins. Comparison of the active fractions with the protein pattern on SDS PAGE (fig. 3) reveals a 40-45 kDa protein as the most likely candidate for 9-(l,6)-glucanase. This result, i.e. the low apparent molecular weight after gel filtration, could be due to an affinity 25 for the column material. It has been reported that fungal cell wall hydrolases can display affinity for Sephacryl supports (Cruz de la, J. et al., J. Bacteriology 177, No 7, 1864-1871, 1995; Cruz de la, J. et al., Eur. J. Biochem. 206, 856-867, 1992; Tangarore, H. et al., Appl. Environ. Microbiol. 55, 177-184, 1989) and thus are 30 retarded to a certain extend on a gel filtration column. 9-(l,6) glucanase containing fractions were pooled, concentrated and subjected to Mono P chromatophocussing chromatography. Starting pH was pH 7.0. Proteins were eluted with a negative pH gradient ending at pH 4.0. The E-(l,6)-glucanase activity eluted from the column at 35 pH 6.7 (fig. 4). SDS-PAGE showed one band with an apparent molecular weight of 40-45kDa (fig. 5). Pool # 2. 23 WO 98/49331 PCT/EP98/02580 The antifungal activity elutes from the gel-filtration column (fig. 6) at about 88kDa, based on standard marker proteins. Comparison of the active fractions with the protein pattern on SDS PAGE (fig. 7) did not result in the determination of a single 5 protein band as the most likely candidate for 9-(l,6)-glucanase. The fraction containing the least protein bands (fraction 16) was subsequently subjected to Mono P chromatofocussing chromatography starting at pH 7.0. Proteins were eluted with a negative pH gradient ending at pH 4.0. The 9-(l,6)-glucanase activity was found 10 in the flow-through of the column, indicating an isoelectric point of 6.8 or higher (fig. 8). SDS-PAGE of the S-(l,6)-glucanase containing fractions (fig. 9) showed two bands. Comparison of this gel (fig. 9) with the SDS-PAGE patterns after gel-filtration chromatography (fig. 7) and the respective 8-(l,6)-glucanase 15 activities, showed that 9-(,6)-glucanase corresponds to a protein band with an apparent molecular weight of about 50kDa. This band is indicated with an arrow in fig. 7 and fig. 9. These fractions did not contain 8(1,3) glucanase activity. 20 Pool # 3. The antifungal activity elutes from the gel-filtration column at the same position as for pool no.2, 88kDa (fig. 10). Kinetic properties of E-(1,6)-glucanase activities. 25 The enzyme activity was measured at different substrate concentrations. A Km of 0.13mg pustulan per ml was calculated (fig. 11), which is about one order of magnitude lower then the Km described for E-(l,6)-glucanase from Trichoderma harzianum (Cruz de la, J. et al., J. Bacteriology 177, No 7, 1864-1871, 1995; and 30 patent no W095/31534). Example 3 In vitro antifungal assay on fungi. 35 The antifungal activity of proteins is measured in a microtiter plate assay. Each well of a 96-well microtiter dish contained 75 1l of potato dextrose agar containing 450 spores. The spore solution is added to PDA (0.75% agar, pH 4.9 at 39 0 C) just 24 WO 98/49331 PCT/EP98/02580 prior to filling of the microtiterplate wells. On top of this, 75il filter sterilized (0.22 pnm filter) protein solution is added. The tests are carried out in microtiter plates at 20 0 C. At several time points after the initiation of incubation the fungus is monitored 5 in a microtiter plate reader at 620nm. Synergy in antifungal properties of AP24 and 91-6 glucanase Spores of Fusarium oxysporum, Penicillium roqueforti, or 10 Paecilomyces variottii are used in the antifungal assays. AP24 or S-(l-6)-glucanase from Trichoderma harzianum are added seperately at a final concentration of 5pg/ml or are added in combination (5 tg/ml of each). AP24 was purified according to WO91/18984, Z-(l 6)-glucanase was purified from a Pichia pastoris expression system 15 according to Lora, J.M. et al., Mol. Gen. Genet., 247, 639-645, 1995; Bom, I.J. et al., Biochim. Biophys. Acta, General subjects, submitted 1998. AP 24 alone or 9-(l-6)-glucanase alone did not result in inhibition of fungal growth. AP24 in combination with 9 (l-6)-glucanase (5gg/ml of each) resulted in strong inhibition of 20 fungal growth (see figures 12, 13, 14). 25 WO 98/49331 PCT/EP98/02580 SEQUENCE LISTING (1) GENERAL INFORMATION: 5 (i) APPLICANT: (A) NAME: MOGEN International nv (B) STREET: Einsteinweg 97 (C) CITY: Leiden 10 (E) COUNTRY: The Netherlands (F) POSTAL CODE (ZIP): 2333 CB (G) TELEPHONE: (31)-71-5258282 (H) TELEFAX: (31)-71-5221471 15 (ii) TITLE OF INVENTION: Antifungal composition, and hosts incorporating same. (iii) NUMBER OF SEQUENCES: 2 20 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO) 25 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: 30 (A) LENGTH: 741 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear 35 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO 40 (vi) ORIGINAL SOURCE: (A) ORGANISM: Nicotiana tabacum (vii) IMMEDIATE SOURCE: 45 (B) CLONE: pMOG404 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..739 50 26 WO 98/49331 PCT/EP98/02580 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: ATG GGC AAC TTG AGA TCT TCT TTT GTT TTC TTC CTC CTT GCC TTG GTG 48 Met Gly Asn Leu Arg Ser Ser Phe Val Phe Phe Leu Leu Ala Leu Val 5 1 5 10 15 ACT TAT ACT TAT GCT GCC ACT ATC GAG GTC CGA AAC AAC TGT CCG TAC 96 Thr Tyr Thr Tyr Ala Ala Thr Ile Glu Val Arg Asn Asn Cys Pro Tyr 20 25 30 10 ACC GTT TGG GCG GCG TCG ACA CCC ATA GGC GGT GGC CGG CGT CTC GAT 144 Thr Val Trp Ala Ala Ser Thr Pro Ile Gly Gly Gly Arg Arg Leu Asp 35 40 45 15 CGA GGC CAA ACT TGG GTG ATC AAT GCG CCA CGA GGT ACT AAA ATG GCA 192 Arg Gly Gln Thr Trp Val Ile Asn Ala Pro Arg Gly Thr Lys Met Ala 50 55 60 CGT GTA TGG GGC CGT ACT AAT TGT AAC TTC AAT GCT GCT GGT AGG GGT 240 20 Arg Val Trp Gly Arg Thr Asn Cys Asn Phe Asn Ala Ala Gly Arg Gly 65 70 75 80 ACG TGC CAA ACC GGT GAC TGT GGT GGA GTC CTA CAG TGC ACC GGG TGG 288 Thr Cys Gln Thr Gly Asp Cys Gly Gly Val Leu Gln Cys Thr Gly Trp 25 85 90 95 GGT AAA CCA CCA AAC ACC TTG GCT GAA TAC GCT TTG GAC CAA TTC AGT 336 Gly Lys Pro Pro Asn Thr Leu Ala Glu Tyr Ala Leu Asp Gln Phe Ser 100 105 110 30 GGT TTA GAT TTC TGG GAC ATT TCT TTA GTT GAT GGA TTC AAC ATT CCG 384 Gly Leu Asp Phe Trp Asp Ile Ser Leu Val Asp Gly Phe Asn Ile Pro 115 120 125 35 ATG ACT TTC GCC CCG ACT AAC CCT AGT GGA GGG AAA TGC CAT GCA ATT 432 Met Thr Phe Ala Pro Thr Asn Pro Ser Gly Gly Lys Cys His Ala Ile 130 135 140 CAT TGT ACG GCT AAT ATA AAC GGC GAA TGT CCC CGC GAA CTT AGG GTT 480 40 His Cys Thr Ala Asn Ile Asn Gly Glu Cys Pro Arg Glu Leu Arg Val 145 150 155 160 CCC GGA GGA TGT AAT AAC CCT TGT ACT ACA TTC GGA GGA CAA CAA TAT 528 Pro Gly Gly Cys Asn Asn Pro Cys Thr Thr Phe Gly Gly Gln Gln Tyr 45 165 170 175 TGT TGC ACA CAA GGA CCT TGT GGT CCT ACA TTT TTC TCA AAA TTT TTC 576 Cys Cys Thr Gln Gly Pro Cys Gly Pro Thr Phe Phe Ser Lys Phe Phe 180 185 190 50 AAA CAA AGA TGC CCT GAT GCC TAT AGC TAC CCA CAA GAT GAT CCT ACT 624 Lys Gln Arg Cys Pro Asp Ala Tyr Ser Tyr Pro Gln Asp Asp Pro Thr 195 200 205 55 AGC ACT TTT ACT TGC CCT GGT GGT AGT ACA AAT TAT AGG GTT ATC TTT 672 Ser Thr Phe Thr Cys Pro Gly Gly Ser Thr Asn Tyr Arg Val Ile Phe 210 215 220 27 WO 98/49331 PCT/EP98/02580 TGT CCT AAT GGT CAA GCT CAC CCA AAT TTT CCC TTG GAA ATG CCT GGA 720 Cys Pro Asn Gly Gln Ala His Pro Asn Phe Pro Leu Glu Met Pro Gly 225 230 235 240 5 AGT GAT GAA GTG GCT AAG T AG 741 Ser Asp Glu Val Ala Lys 245 10 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 246 amino acids (B) TYPE: amino acid 15 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: 20 Met Gly Asn Leu Arg Ser Ser Phe Val Phe Phe Leu Leu Ala Leu Val 1 5 10 15 Thr Tyr Thr Tyr Ala Ala Thr Ile Glu Val Arg Asn Asn Cys Pro Tyr 25 20 25 30 Thr Val Trp Ala Ala Ser Thr Pro Ile Gly Gly Gly Arg Arg Leu Asp 35 40 45 30 Arg Gly Gln Thr Trp Val Ile Asn Ala Pro Arg Gly Thr Lys Met Ala 50 55 60 Arg Val Trp Gly Arg Thr Asn Cys Asn Phe Asn Ala Ala Gly Arg Gly 65 70 75 80 35 Thr Cys Gln Thr Gly Asp Cys Gly Gly Val Leu Gln Cys Thr Gly Trp 85 90 95 Gly Lys Pro Pro Asn Thr Leu Ala Glu Tyr Ala Leu Asp Gln Phe Ser 40 100 105 110 Gly Leu Asp Phe Trp Asp Ile Ser Leu Val Asp Gly Phe Asn Ile Pro 115 120 125 45 Met Thr Phe Ala Pro Thr Asn Pro Ser Gly Gly Lys Cys His Ala Ile 130 135 140 His Cys Thr Ala Asn Ile Asn Gly Glu Cys Pro Arg Glu Leu Arg Val 145 150 155 160 50 Pro Gly Gly Cys Asn Asn Pro Cys Thr Thr Phe Gly Gly Gln Gln Tyr 165 170 175 Cys Cys Thr Gln Gly Pro Cys Gly Pro Thr Phe Phe Ser Lys Phe Phe 55 180 185 190 Lys Gln Arg Cys Pro Asp Ala Tyr Ser Tyr Pro Gln Asp Asp Pro Thr 195 200 205 28 WO 98/49331 PCT/EP98/02580 Ser Thr Phe Thr Cys Pro Gly Gly Ser Thr Asn Tyr Arg Val Ile Phe 210 215 220 5 Cys Pro Asn Gly Gln Ala His Pro Asn Phe Pro Leu Glu Met Pro Gly 225 230 235 240 Ser Asp Glu Val Ala Lys 245 29

Claims (14)

1. An isolated protein which has 9-(l,6)-glucanase activity, which is obtainable from an edible fungus. 5
2. An isolated protein according to claim 1 and which can be purified by performing the following steps: a. making an extract of material from an edible fungus; b. precipitate the extract with ammonium sulphate 10 c. purify the precipitate by adsorption to pustulan particles, d. chromatofocus the purified material on a Mono P column, and, if necessary, e. gel filtration. 15 3. An isolated protein according to claim 1 and which can be purified by performing the following steps: a. making an extract of material from an edible fungus; b. separating fractions on hydrophobic interaction chromotography; c. separating fractions on cation exchange chromatography; 20 d. gel filtration; and optionally e. chromatofocusing; thereby after step b) to e) assaying the fractions obtained on 9-(l,6) glucanase activity and continuing with the fractions found to have said activity. 25
4. The protein according to any of claims 1 to 3, characterized in that it has a molecular weight of about 50-51 kD.
5. The protein according to any of claims 1 to 4, characterized 30 in that the edible fungus is selected from the group consisting of Lentinus edodes, Volvariella spp., Tricholoma matsutake, Agaricus spp., Tuber uncinatum, Tuber melanosporum, Tuber spp., Stephensia spp., Cantharellus spp., Pleurotus spp., Coprinus spp., Lepiota spp., Marasmius spp., Polysporus spp., Verpa spp., Tricholoma spp., 35 Terfezia spp., Morchella spp., Cyttaria spp and fungi routinely used in the production of cheese such as Penicillium roqueforti and P. camemberti 30 WO 98/49331 PCT/EP98/02580
6. Antifungal composition comprising a S-(l,6)-glucanase.
7. Antifungal composition of claim 6, characterized in that the
9-(l,6)-glucanase is the protein according to any of claim 1-5. 5 8. Antifungal composition according to claim 6 or 7, further comprising an osmotin. 9. Antifungal composition according to claim 8, characterized in 10 that the osmotin is AP24.
10. Method for the production of pathogen resistant plants by transforming them with a chimeric DNA comprising a sequence coding for a S-(l,6)-glucanase. 15
11. Method according to claim 10, characterized in that the plants are also transformed with a chimeric DNA comprising a sequence coding for an osmotin. 20 12. Method according to claim 11, characterized in that the osmotin comprises the amino acid sequence of SEQ ID NO:2.
13. Method according to claim 12, characterized in that the sequence coding for the osmotin comprises the nucleotide sequence 25 of SEQ ID NO:l.
14. Method according to any of claims 10 to 13, characterized in that the S-(l,6)-glucanase is of fungal origin. 30 15. Method according to claim 14, characterized in that the fungus is Trichoderma harzianum.
16. Method according to claim 14, characterized in that the fungus is an edible mushroom. 35 31 WO 98/49331 PCT/EP98/02580
17. Method according to claim 16, characterized in that the fungus is selected from the group consisting of Lentinus edodes, Volvariella spp., Tricholoma matsutake, Agaricus spp., Tuber uncinatum, Tuber melanosporum, Tuber spp., Stephensia spp., 5 Cantharellus spp., Pleurotus spp., Coprinus spp., Lepiota spp., Marasmius spp., Polysporus spp., Verpa spp., Tricholoma spp., Terfezia spp., Morchella spp., Cyttaria spp and fungi routinely used in the production of cheese such as Penicillium roqueforti and P. camemberti. 10
18. Method according to any of claims 10-17 characterized in that the osmotin or the 9-(l,6)-glucanase is targeted to the extracellular space. 15 19. Method according to any of claims 10-18, characterized in that the plants are also transformed with a sequence coding for a protein selected from the group consisting of chitinases, 8-(l,3) glucanases, chitobiases, N-acetyl-g-glucosaminidases, basic PR-1, antifungal proteins (AFP's), phospholipase B, proteases, defensins, 20 cecropins, thionins, mellitins, magainins, attacins, dipterins, cacrutins, xenopsins, and hybrids thereof. 32
AU77608/98A 1997-04-29 1998-04-27 Antifungal composition containing beta-(1,6)-glucanase, and hosts incorporating same Ceased AU743529B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97201254 1997-04-29
EP97201254 1997-04-29
PCT/EP1998/002580 WO1998049331A1 (en) 1997-04-29 1998-04-27 Antifungal composition containing beta-(1,6)-glucanase, and hosts incorporating same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU91445/01A Division AU9144501A (en) 1997-04-29 2001-11-21 Antifungal composition containing beta-(1,6)-glucanase and hosts incorporating same

Publications (2)

Publication Number Publication Date
AU7760898A true AU7760898A (en) 1998-11-24
AU743529B2 AU743529B2 (en) 2002-01-31

Family

ID=8228266

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77608/98A Ceased AU743529B2 (en) 1997-04-29 1998-04-27 Antifungal composition containing beta-(1,6)-glucanase, and hosts incorporating same

Country Status (7)

Country Link
EP (1) EP1027445A1 (en)
JP (1) JP2001523962A (en)
AR (1) AR015112A1 (en)
AU (1) AU743529B2 (en)
CA (1) CA2288074A1 (en)
WO (1) WO1998049331A1 (en)
ZA (1) ZA983554B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530414A (en) 1998-11-25 2002-09-17 バーゼル、ポリプロピレン、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング Metallocene purification method
CA2839066A1 (en) 1999-12-16 2001-06-21 Monsanto Technology Llc Hybrid promoter for use in plants
WO2002059333A2 (en) * 2001-01-23 2002-08-01 Ziyu Dai Gene promoters isolated from potato and use thereof
WO2002061043A2 (en) * 2001-01-29 2002-08-08 Cargill, Incorporated Fungal resistant transgenic plants
JP2004189737A (en) * 2002-11-28 2004-07-08 Keiichiro Hiyama Antifungal agent
CN104974225B (en) * 2015-07-22 2018-04-27 中国农业大学 Matsutake polypeptide, Fructificatio Tricholomatis Matsutakis extract and their application
FR3090275B1 (en) * 2018-12-21 2022-04-29 Covertis BIOLOGICALLY ACTIVE SUBSTANCE, METHOD FOR MANUFACTURING IT AND ITS USE AS A PROTECTIVE AGENT FOR A BIOLOGICAL TISSUE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69368A (en) * 1983-07-28 1990-03-19 Yissum Res Dev Co Fungicidal compositions containing trichoderma harzianum t-35 active against fusarium and method for using them
EP0460753A3 (en) * 1990-06-07 1992-04-15 Mogen International N.V. New antifungal preparations, process for making such preparations, process for obtaining plants with decreased susceptibility to fungi
AU5085993A (en) * 1992-09-28 1994-04-26 Monsanto Company Method of controlling plant pathogenic fungi
US5474926A (en) * 1992-12-15 1995-12-12 Cornell Research Foundation, Inc. N-acetyl-β-glucosaminidase isolated from Trichoderma harzianum
US5530187A (en) * 1993-07-16 1996-06-25 The Salk Institute For Biological Studies Transgenic plants containing multiple disease resistance genes
JPH10500296A (en) * 1994-05-11 1998-01-13 ノボ ノルディスク アクティーゼルスカブ Enzyme having β- (1-6) -endoglucanase activity

Also Published As

Publication number Publication date
CA2288074A1 (en) 1998-11-05
AU743529B2 (en) 2002-01-31
ZA983554B (en) 1998-10-29
WO1998049331A1 (en) 1998-11-05
AR015112A1 (en) 2001-04-18
JP2001523962A (en) 2001-11-27
EP1027445A1 (en) 2000-08-16

Similar Documents

Publication Publication Date Title
US5689045A (en) Transgenic pathogen-resistant plant
EP0440304B1 (en) Fungal resistant plants, process for obtaining fungal resistant plants and recombinant polynucleotides for use therein
AU667825B2 (en) Biocidal proteins capable of isolation from brassicaceae, compostiae and leguminosae families
US5993808A (en) Chitinase, DNA coding therefor and plants containing same
AU718274B2 (en) Antifungal proteins, DNA coding therefore, and hosts incorporating same
US5994625A (en) Antifungal chitin binding proteins and DNA coding therefor
WO1995005467A9 (en) Chitinase, dna coding therefor and plants containing same
AU743529B2 (en) Antifungal composition containing beta-(1,6)-glucanase, and hosts incorporating same
EP0746622B1 (en) Antifungal proteins, dna coding therefor, and hosts incorporating same
AU9144501A (en) Antifungal composition containing beta-(1,6)-glucanase and hosts incorporating same
EP0667905A1 (en) Antifungal chitin binding proteins and dna coding therefor
USRE39238E1 (en) Transgenic pathogen-resistant organism
ZA200005115B (en) Salicylic acid pathway genes and their use for the induction of resistance in plants.

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: SYNGENTA MOGEN BV

Free format text: FORMER NAME: MOGEN INTERNATIONAL N.V.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired